Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.

Ito R, Umehara K, Suzuki S, Kitamura K, Nunoya KI, Yamaura Y, Imawaka H, Izumi S, Wakayama N, Komori T, Anzai N, Akita H, Furihata T.

Mol Pharm. 2019 Nov 4;16(11):4461-4471. doi: 10.1021/acs.molpharmaceut.9b00519. Epub 2019 Oct 15.

PMID:
31573814
2.

Unique Hydrolysis of an Ester-Type Prodrug of Levodopa in Human Plasma: Relay-Type Role Sharing between Alpha-1 Acid Glycoprotein and Human Serum Albumin.

Kono K, Fukuchi Y, Okawa H, Nunoya KI, Imawaka H, Watanabe H, Maruyama T.

Mol Pharm. 2019 Oct 7;16(10):4131-4138. doi: 10.1021/acs.molpharmaceut.9b00435. Epub 2019 Aug 28.

PMID:
31433646
3.

Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.

Asaumi R, Menzel K, Lee W, Nunoya KI, Imawaka H, Kusuhara H, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):845-857. doi: 10.1002/psp4.12457. Epub 2019 Sep 5.

4.

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Asaumi R, Toshimoto K, Tobe Y, Hashizume K, Nunoya KI, Imawaka H, Lee W, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):186-196. doi: 10.1002/psp4.12275. Epub 2018 Feb 5.

5.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases.

Kurata H, Kusumi K, Otsuki K, Suzuki R, Kurono M, Komiya T, Hagiya H, Mizuno H, Shioya H, Ono T, Takada Y, Maeda T, Matsunaga N, Kondo T, Tominaga S, Nunoya KI, Kiyoshi H, Komeno M, Nakade S, Habashita H.

J Med Chem. 2017 Dec 14;60(23):9508-9530. doi: 10.1021/acs.jmedchem.7b00785. Epub 2017 Nov 21.

PMID:
29120624
6.

Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism.

Fukuchi Y, Toshimoto K, Mori T, Kakimoto K, Tobe Y, Sawada T, Asaumi R, Iwata T, Hashimoto Y, Nunoya KI, Imawaka H, Miyauchi S, Sugiyam Y.

J Pharm Sci. 2017 Sep;106(9):2704-2714. doi: 10.1016/j.xphs.2017.04.052. Epub 2017 Apr 30.

PMID:
28465151
7.

Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.

Matsunaga N, Kaneko N, Staub AY, Nakanishi T, Nunoya K, Imawaka H, Tamai I.

Drug Metab Dispos. 2016 Jan;44(1):16-27. doi: 10.1124/dmd.115.067074. Epub 2015 Oct 26.

PMID:
26502773
8.

Evaluation of hepatic disposition of paroxetine using sandwich-cultured rat and human hepatocytes.

Matsunaga N, Nunoya K, Okada M, Ogawa M, Tamai I.

Drug Metab Dispos. 2013 Apr;41(4):735-43. doi: 10.1124/dmd.112.049817. Epub 2013 Jan 9.

PMID:
23303441
9.

In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes.

Yoneda K, Matsumoto I, Sutoh F, Higashi R, Nunoya K, Nakade S, Miyata Y, Ogawa M.

Biol Pharm Bull. 2009 Apr;32(4):688-93.

10.

Mutational analysis of polar amino acid residues within predicted transmembrane helices 10 and 16 of multidrug resistance protein 1 (ABCC1): effect on substrate specificity.

Zhang DW, Nunoya K, Vasa M, Gu HM, Cole SP, Deeley RG.

Drug Metab Dispos. 2006 Apr;34(4):539-46. Epub 2006 Jan 13.

PMID:
16415113
11.
12.

Cloning and Characterization of the Murine and Rat mrp1 Promoter Regions.

Muredda M, Nunoya K, Burtch-Wright RA, Kurz EU, Cole SP, Deeley RG.

Mol Pharmacol. 2003 Nov;64(5):1259-69.

PMID:
14573776
13.

Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1).

Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG.

Drug Metab Dispos. 2003 Aug;31(8):1016-26.

PMID:
12867490
14.
15.

The house musk shrew (Suncus murinus): a unique animal with extremely low level of expression of mRNAs for CYP3A and flavin-containing monooxygenase.

Mushiroda T, Yokoi T, Itoh K, Nunoya K, Nakagawa T, Kubota M, Takahara E, Nagata O, Kato H, Kamataki T.

Comp Biochem Physiol C Toxicol Pharmacol. 2000 Jul;126(3):225-34.

PMID:
11048672
16.

Genetic polymorphism of CYP2A6 in relation to cancer.

Kamataki T, Nunoya K, Sakai Y, Kushida H, Fujita K.

Mutat Res. 1999 Jul 16;428(1-2):125-30.

PMID:
10517986
17.
18.

A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans.

Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, Kamataki T.

J Pharmacol Exp Ther. 1999 Apr;289(1):437-42.

PMID:
10087035
19.

A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamataki T.

Pharmacogenetics. 1998 Jun;8(3):239-49.

PMID:
9682269
20.

Role of human cytochrome P4502A6 in C-oxidation of nicotine.

Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y.

Drug Metab Dispos. 1996 Nov;24(11):1212-7.

PMID:
8937855
21.

(+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes.

Nunoya K, Yokoi Y, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C, Kamataki T.

J Pharmacol Exp Ther. 1996 May;277(2):768-74.

PMID:
8627557
22.

Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.

Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y.

J Pharmacol Exp Ther. 1996 May;277(2):1010-5.

PMID:
8627511
23.

Supplemental Content

Loading ...
Support Center